CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.99BCNY1.04B · vs all stocks (USD)
Revenue (TTM)
287.11MCNY42.70M · vs all stocks (USD)
Profit Margin
-155.08%Beta
0.2900xvs all stocks
52-Week Change
-0.33%vs all stocks
Market Capitalization
6.99BCNY1.04B · vs all stocks (USD)
Enterprise Value
6.26BCNY930.99M · vs all stocks (USD)
Forward P/E
-34.40xPrice to Sales (TTM)
25.71xPrice to Book (MRQ)
4.95xEnterprise to Revenue
21.80xEnterprise to EBITDA
-13.90xGross Margin
72.56%Profit Margin
-155.08%Operating Margin
-161.72%Return on Assets (TTM)
-14.15%Return on Equity (TTM)
-27.59%Revenue (TTM)
287.11MCNY42.70M · vs all stocks (USD)
Revenue per Share (TTM)
0.5090CNYUpdated Aug 21, 2026Quarterly Revenue Growth
16.30%Gross Profit (TTM)
208.54MCNY31.01M · vs all stocks (USD)
EBITDA (TTM)
-450.26MCNY-66.96M · vs all stocks (USD)
Net Income (TTM)
-445.25MCNY-66.21M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.54%Operating Cash Flow (TTM)
-425.94MCNY-63.34M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-320.31MCNY-47.63M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-13.28MCNYFY2025 · Dec 31, 2025Revenue
277.12MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
71.96MCNYFY2025 · Dec 31, 2025Gross Profit
205.16MCNYFY2025 · Dec 31, 2025Operating Income
-441.63MCNY-65.67M · vs all stocks (USD)
Pre-tax Income
-433.41MCNYFY2025 · Dec 31, 2025Income Tax Expense
-660.49KCNYFY2025 · Dec 31, 2025Net Income
-432.75MCNYFY2025 · Dec 31, 2025EBIT
-425.13MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-392.11MCNYFY2025 · Dec 31, 2025Research & Development
282.63MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
215.21MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.69MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.27MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.7400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.7400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
562.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
562.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-432.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
16.36MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-501.29MCNYFY2025 · Dec 31, 2025Free Cash Flow
-520.40MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
450.95MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-432.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
14.49MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-68.02MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-15.01MCNYFY2025 · Dec 31, 2025Capital Expenditures
-19.11MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.63BCNYFY2025 · Dec 31, 2025Sale of Investments
1.69BCNYFY2025 · Dec 31, 2025Other Investing Activity
1.87MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
37.62MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
288.05MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-66.20MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-4.08MCNYFY2025 · Dec 31, 2025Other Financing Charges
-11.60MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
206.16MCNYFY2025 · Dec 31, 2025Shares Outstanding
571.17MSharesUpdated Aug 21, 2026Float Shares
370.03MSharesUpdated Aug 21, 2026% Held by Insiders
39.90%vs all stocks
% Held by Institutions
2.58%vs all stocks
Total Cash (MRQ)
1.38BCNY205.62M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.46CNYUpdated Aug 21, 2026Total Debt (MRQ)
357.29MCNY53.13M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2462xCurrent Ratio (MRQ)
4.07xBook Value per Share (MRQ)
2.61CNYUpdated Aug 21, 2026Total Assets
2.06BCNY305.97M · vs all stocks (USD)
Total Current Assets
1.76BCNYFY2025 · Dec 31, 2025Total Liabilities
494.44MCNYFY2025 · Dec 31, 2025Total Non-current Assets
295.74MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
92.04MCNYFY2025 · Dec 31, 2025Total Current Liabilities
402.40MCNYFY2025 · Dec 31, 2025Cash
770.95MCNYFY2025 · Dec 31, 2025Cash Equivalents
8.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
779.45MCNYFY2025 · Dec 31, 2025Other Short-term Investments
668.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
98.56MCNYFY2025 · Dec 31, 2025Inventory
21.92MCNYFY2025 · Dec 31, 2025Accounts Payable
59.59MCNYFY2025 · Dec 31, 2025Short-term Debt
257.71MCNYFY2025 · Dec 31, 2025Long-term Debt
87.44MCNYFY2025 · Dec 31, 2025Common Stock (Book)
571.17MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.84BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.56BCNY232.44M · vs all stocks (USD)
Treasury Stock
50.06MCNYFY2025 · Dec 31, 202552-Week Low
8.93CNYUpdated Aug 21, 202652-Week High
18.11CNYUpdated Aug 21, 202652-Week Change
-0.33%vs all stocks
Beta
0.2900xvs all stocks
50-Day MA
11.82CNYUpdated Aug 21, 2026200-Day MA
12.16CNYUpdated Aug 21, 2026Avg 10-Day Volume
15.57MSharesUpdated Aug 21, 2026Avg 30-Day Volume
23.95MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.7900CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.73Profit Margin: -1.55
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.65
Altman Z-Score 7.48: safe zoneNotable
Altman Z-Score: 7.48
High structural barrier to entryNotable
Barrier to Entry: 39,070.985
Consistent revenue growth patternNotable
Growth Consistency Score: 0.59
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Animal Husbandry Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zylox-Tonbridge Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule